Fast Five Quiz: Treatment of Chronic Migraine

Jasvinder P. Chawla, MD, MBA 


March 07, 2022

Most oral preventive pharmacologic therapies for chronic migraine have been shown to have only modest efficacies and therapeutic gains < 50% compared with placebo. Improved efficacy and tolerability may be achieved with onabotulinumtoxinA and small-molecule calcitonin gene–related peptide receptor antagonists (which are administered subcutaneously).

Antiepileptics, antidepressants, and antihypertensives may be considered in the first line for preventive therapy given their affordability. For any of these agents, migraine prophylaxis should not be deemed a failure until the maximum tolerable dose has been administered for a minimum of 30 days. Onset of positive treatment response can be quite prolonged.

Learn more about the various drug classes used in the treatment of chronic migraine.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.